{"id":53981,"date":"2023-02-16T08:03:39","date_gmt":"2023-02-16T07:03:39","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\/"},"modified":"2023-02-16T08:03:39","modified_gmt":"2023-02-16T07:03:39","slug":"eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\/","title":{"rendered":"Eurofins Viracor Launches Ground-Breaking Test for Assessing Expansion and Persistence of CAR-T Therapy in Cancer Patients"},"content":{"rendered":"
\n

\nEurofins Viracor ExPeCT\u2122 CAR-T multiplexed quantitative real-time PCR (qPCR) assay provides a powerful diagnostic tool to monitor and optimise CAR-T therapy involving patients with pre-B cell acute lymphoblastic<\/i> <\/i>leukemia and B cell lymphomas<\/i><\/b>\n<\/p>\n

LUXEMBOURG–(BUSINESS WIRE)–Eurofins (Paris:ERF):\n<\/p>\n

<\/a><\/p>\n

\nEurofins Viracor LLC, part of the Eurofins network of companies, and a leader in testing for infectious disease, immunology, and allergy, today announces the launch of a ground-breaking test that can assess the expansion and persistence of Chimeric Antigen Receptor T-Cell (CAR-T) therapy in patients with pre-B cell acute lymphoblastic leukemia and B cell lymphomas.\n<\/p>\n

\nThe test, based on a method developed by Eurofins Viracor, is designed to help clinicians better understand how CAR-T therapy is performing for their patients. CAR-T therapy is a revolutionary form of immunotherapy that uses genetically engineered T-cells to attack cancer cells and has shown promising results in treating a variety of cancers.\n<\/p>\n

\nResearch has demonstrated that the persistence and expansion of CAR-T therapy are important indicators of how long the therapy is likely to remain effective in the patient. The test is designed to provide clinicians with an accurate and comprehensive assessment of the CAR-T cell population in the patient\u2019s body and may offer insights to therapy effectiveness.\n<\/p>\n

\nThe launch of this test marks an important step forward in the evaluation and management of CAR-T therapy in cancer patients. It is expected to be a valuable tool in helping clinicians to make more informed decisions about the best course of treatment for their patients.\n<\/p>\n

\nNotes to Editors:<\/b>\n<\/p>\n

\nAbout Eurofins\u2013 the global leader in bio-analysis
\n
<\/b>Eurofins is Testing for Life. With 61,000 staff across a network of 940 laboratories in 59 countries, Eurofins\u2019 companies offer a portfolio of over 200,000 analytical methods.
\n
Eurofins Shares are listed on Euronext Paris Stock Exchange.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor more information, please visit <\/b>www.eurofins.com<\/a> or contact:<\/b>\n<\/p>\n

\nInvestor Relations
\n
Eurofins Scientific SE
\n
Phone: +32 2 766 1620
\n
E-mail: ir@eurofins.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Eurofins Viracor ExPeCT\u2122 CAR-T multiplexed quantitative real-time PCR (qPCR) assay provides a powerful diagnostic tool to monitor and optimise CAR-T therapy involving patients with pre-B cell acute lymphoblastic leukemia and B cell lymphomas LUXEMBOURG–(BUSINESS WIRE)–Eurofins (Paris:ERF): Eurofins Viracor LLC, part of the Eurofins network of companies, and a leader in testing for infectious disease, immunology, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53981","6":"format-standard","7":"category-industry"},"yoast_head":"\nEurofins Viracor Launches Ground-Breaking Test for Assessing Expansion and Persistence of CAR-T Therapy in Cancer Patients - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eurofins Viracor Launches Ground-Breaking Test for Assessing Expansion and Persistence of CAR-T Therapy in Cancer Patients - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Eurofins Viracor ExPeCT\u2122 CAR-T multiplexed quantitative real-time PCR (qPCR) assay provides a powerful diagnostic tool to monitor and optimise CAR-T therapy involving patients with pre-B cell acute lymphoblastic leukemia and B cell lymphomas LUXEMBOURG–(BUSINESS WIRE)–Eurofins (Paris:ERF): Eurofins Viracor LLC, part of the Eurofins network of companies, and a leader in testing for infectious disease, immunology, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-16T07:03:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230215005674\/en\/318625\/21\/EUROFINS_jpg.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Eurofins Viracor Launches Ground-Breaking Test for Assessing Expansion and Persistence of CAR-T Therapy in Cancer Patients\",\"datePublished\":\"2023-02-16T07:03:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\\\/\"},\"wordCount\":329,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230215005674\\\/en\\\/318625\\\/21\\\/EUROFINS_jpg.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\\\/\",\"name\":\"Eurofins Viracor Launches Ground-Breaking Test for Assessing Expansion and Persistence of CAR-T Therapy in Cancer Patients - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230215005674\\\/en\\\/318625\\\/21\\\/EUROFINS_jpg.jpg\",\"datePublished\":\"2023-02-16T07:03:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230215005674\\\/en\\\/318625\\\/21\\\/EUROFINS_jpg.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230215005674\\\/en\\\/318625\\\/21\\\/EUROFINS_jpg.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eurofins Viracor Launches Ground-Breaking Test for Assessing Expansion and Persistence of CAR-T Therapy in Cancer Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eurofins Viracor Launches Ground-Breaking Test for Assessing Expansion and Persistence of CAR-T Therapy in Cancer Patients - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\/","og_locale":"en_US","og_type":"article","og_title":"Eurofins Viracor Launches Ground-Breaking Test for Assessing Expansion and Persistence of CAR-T Therapy in Cancer Patients - Pharma Trend","og_description":"Eurofins Viracor ExPeCT\u2122 CAR-T multiplexed quantitative real-time PCR (qPCR) assay provides a powerful diagnostic tool to monitor and optimise CAR-T therapy involving patients with pre-B cell acute lymphoblastic leukemia and B cell lymphomas LUXEMBOURG–(BUSINESS WIRE)–Eurofins (Paris:ERF): Eurofins Viracor LLC, part of the Eurofins network of companies, and a leader in testing for infectious disease, immunology, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-16T07:03:39+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230215005674\/en\/318625\/21\/EUROFINS_jpg.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Eurofins Viracor Launches Ground-Breaking Test for Assessing Expansion and Persistence of CAR-T Therapy in Cancer Patients","datePublished":"2023-02-16T07:03:39+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\/"},"wordCount":329,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230215005674\/en\/318625\/21\/EUROFINS_jpg.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\/","url":"https:\/\/pharma-trend.com\/en\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\/","name":"Eurofins Viracor Launches Ground-Breaking Test for Assessing Expansion and Persistence of CAR-T Therapy in Cancer Patients - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230215005674\/en\/318625\/21\/EUROFINS_jpg.jpg","datePublished":"2023-02-16T07:03:39+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230215005674\/en\/318625\/21\/EUROFINS_jpg.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230215005674\/en\/318625\/21\/EUROFINS_jpg.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Eurofins Viracor Launches Ground-Breaking Test for Assessing Expansion and Persistence of CAR-T Therapy in Cancer Patients"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53981","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53981"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53981\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53981"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53981"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53981"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}